Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2B | Q02880 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | SDHA | P31040 | 2/20 | 0.46 |
| ▸ | CALML3 | P27482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2109002 | 1.00 | TOP2B (0.49) | TOP2BLMNAMAOAMAOBPTGS1 | |
| SCHEMBL29395141 | 1.00 | TOP2B (0.49) | TOP2BLMNAMAOAMAOBPTGS1 | |
| SCHEMBL12342304 | 0.96 | TOP2B (0.51) | TOP2BLMNAMAOAMAOBPTGS1 | |
| SCHEMBL16274030 | 0.96 | TOP2B (0.51) | TOP2BLMNAMAOAMAOBPTGS1 | |
| SCHEMBL21203139 | 0.94 | TOP2B (0.48) | TOP2BLMNAMAOAMAOBPTGS1 | |
| SCHEMBL22795065 | 0.94 | KDM4E (0.46) | TOP2BLMNAMAOBKDM4EALDH1A1 | |
| SCHEMBL22794181 | 0.93 | KDM4E (0.45) | TOP2BLMNAKDM4EALDH1A1HPGD | |
| SCHEMBL28488322 | 0.92 | TOP2B (0.51) | TOP2BLMNAMAOAMAOBPTGS1 | |
| SCHEMBL22642711 | 0.92 | TOP2B (0.51) | TOP2BLMNAMAOAMAOBPTGS1 | |
| SCHEMBL2108803 | 0.92 | TOP2B (0.47) | TOP2BLMNAMAOAMAOBPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392168-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIAL FOR THE PARENTERAL TREATMENT OF PROPHYLAXIS OF BACTERIAL DISEASES | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2020-12-17 | — | — | US | disclosed |
| US-10723746-B2 | Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2020-07-28 | — | — | US | disclosed |
| EP-3517106-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20190111046-A1 | COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMB CHEMIE (DE) | 2019-04-18 | — | — | US | disclosed |
| US-9993469-B2 | Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections | Morphochem Aktiengesellschaft Für Kombinatorishe Chemie (DE) | 2018-06-12 | — | — | US | disclosed |
| US-8501774-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20120142635-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392168-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIAL FOR THE PARENTERAL TREATMENT OF PROPHYLAXIS OF BACTERIAL DISEASES | NQO2, QARS1, RECQL | TOP2B 85/4885LMNA 3394/4885MAOA 2580/4885 |
| US-20190111046-A1 | COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS | OXA1L, NQO2, NQO1 | TOP2B 17/4885LMNA 4306/4885MAOA 2294/4885 |
| US-10723746-B2 | Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases | NQO2, OXA1L, QARS1 | TOP2B 72/4885LMNA 3425/4885MAOA 2656/4885 |
| US-20120142635-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | TOP2B 13/4885LMNA 3615/4885MAOA 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.